TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36383294

Group type: EXPERIMENTAL
Intervention: BT595 (10% Human Normal Immunoglobulin) administered at doses between 0.2 and 0.8 g/kg body weight for approximately 12 months at intervals of either 3 or 4 weeks
Number of subjects: 18
Study: 36383511

Group type: EXPERIMENTAL
Intervention: Mothers with school-aged children
Number of subjects: 848

Group type: COMPARATOR
Intervention: Mothers with 2 children
Number of subjects: 848

Group type: COMPARATOR
Intervention: Mothers with 2 children (school-aged)
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Mothers with 2 children (≤4y)
Number of subjects: 848

Group type: COMPARATOR
Intervention: Mothers with multiple children and only children aged ≤4y
Number of subjects: 848
Study: 36383708

Group type: EXPERIMENTAL
Intervention: Underweight participants (weight-for-age z score <-1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Children who died during the study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pooled analysis of participants
Number of subjects: 0
Study: 36383730

Group type: EXPERIMENTAL
Intervention: V114 (15-valent pneumococcal conjugate vaccine)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Prevnar 13 (PCV13)
Number of subjects: 103
Study: 36383760

Group type: EXPERIMENTAL
Intervention: Professional oral care
Number of subjects: 6244

Group type: COMPARATOR
Intervention: Usual oral care
Number of subjects: 6244
Study: 36383907

Group type: EXPERIMENTAL
Intervention: Radiolabeled monoclonal antibodies (mAbs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibody-drug conjugates (ADCs)
Number of subjects: 0
Study: 36384095

Group type: EXPERIMENTAL
Intervention: Combined inhibition of SHP2 using RMC-4550 and ERK using LY3214996
Number of subjects: 0
Study: 36384183

Group type: EXPERIMENTAL
Intervention: FORS-guided procedures
Number of subjects: 82

Group type: COMPARATOR
Intervention: Non-FORS-guided procedures
Number of subjects: 82
Study: 36384393

Group type: EXPERIMENTAL
Intervention: early-PN
Number of subjects: 1212

Group type: EXPERIMENTAL
Intervention: late-PN
Number of subjects: 1212

Group type: COMPARATOR
Intervention: matched healthy children
Number of subjects: 1212
Study: 36384443

Group type: EXPERIMENTAL
Intervention: Serum levels of insulin-like growth factor-1 (IGF-1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum levels of IGF-1 binding protein-3 (IGFBP-3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum levels of GH receptor (GHR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum levels of GH-binding protein (GHBP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adipose tissue (AT) expression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased fat mass
Number of subjects: 0
Study: 36384465

Group type: EXPERIMENTAL
Intervention: Implementation of a standardized acute KRT pathway including routine monitoring of KPIs and prescriber reports.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline performance of acute KRT before implementation of the pathway.
Number of subjects: 0
Study: 36384544

Group type: EXPERIMENTAL
Intervention: Gamified flipped classroom for 6 weeks
Number of subjects: 128

Group type: COMPARATOR
Intervention: Traditional flipped classrooms
Number of subjects: 128
Study: 36384579

Group type: EXPERIMENTAL
Intervention: ChildTalks+ intervention (4 structured psychoeducational sessions)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no intervention until after the last assessment)
Number of subjects: 66
Study: 36384656

Group type: EXPERIMENTAL
Intervention: Diabetic patients undergoing TAVI
Number of subjects: 11440

Group type: EXPERIMENTAL
Intervention: Insulin treated diabetics
Number of subjects: 11440
Study: 36384907

Group type: EXPERIMENTAL
Intervention: Vibegron 75 mg
Number of subjects: 1286

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1286
Study: 36384966

Group type: EXPERIMENTAL
Intervention: Active rTMS (20 Hz, applied to the bilateral dorsolateral prefrontal cortex, 5x/week for 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 0
Study: 36385011

Group type: EXPERIMENTAL
Intervention: Interferon-lambda treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36385120

Group type: EXPERIMENTAL
Intervention: CYH33 1-60 mg
Number of subjects: 51
Study: 36385136

Group type: EXPERIMENTAL
Intervention: Maximum daily precipitation increase (10 cm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specific humidity increase (g/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High emission assumptions for climate change
Number of subjects: 0
Study: 36385536

Group type: EXPERIMENTAL
Intervention: Oral ixazomib 4 mg weekly until progressive disease or unacceptable adverse events.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Oral ixazomib 4 mg weekly combined with short-course rituximab (4-week course added during month 7).
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Baseline downregulation of proteasome genes, PSMB9 and PSMB8.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccination.
Number of subjects: 33
Study: 36385585

Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training (BPT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptations to BPT targeting emotion regulation (ER)
Number of subjects: 0
Study: 36386029

Group type: EXPERIMENTAL
Intervention: Surfactant (two or more doses)
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Surfactant (one or less doses)
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Overall NARDS incidence
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Aetiological factors
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: BPD and/or death
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Cumulative incidences of NARDS
Number of subjects: 1005
Study: 36386039

Group type: COMPARATOR
Intervention: ColonES assay for ctDNA methylation haplotype patterns
Number of subjects: 1138

Group type: EXPERIMENTAL
Intervention: High preoperative ctDNA methylation levels
Number of subjects: 1138
Study: 36386175

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36386307

Group type: EXPERIMENTAL
Intervention: V-PPG measurement during the 'Ca' position
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: V-PPG measurement during the 'Pra' position
Number of subjects: 424
Study: 36386348

Group type: EXPERIMENTAL
Intervention: Recurrent acute myocarditis episodes
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Genetic testing
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Family history of cardiomyopathy or early sudden cardiac death
Number of subjects: 21
Study: 36386357

Group type: EXPERIMENTAL
Intervention: Single transradial guiding catheter (STGC)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 560
Study: 36386418

Group type: EXPERIMENTAL
Intervention: Intravenous anesthesia with propofol (Group P)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Inhalation anesthesia with sevoflurane (Group S)
Number of subjects: 40
Study: 36386456

Group type: EXPERIMENTAL
Intervention: Nintedanib plus docetaxel
Number of subjects: 137
Study: 36386776

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1.5 mA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 30
Study: 36386914

Group type: EXPERIMENTAL
Intervention: One-day intermittent fasting (IF) combined with protein pacing (4-5 meals/day, >30% protein/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two-day intermittent fasting (IF) combined with protein pacing (4-5 meals/day, >30% protein/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36386926

Group type: EXPERIMENTAL
Intervention: Time-restricted feeding (TRF) intervention for 2 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: No time restrictions (control group)
Number of subjects: 0
Study: 36386937

Group type: EXPERIMENTAL
Intervention: 2 g/day grape polyphenol extract
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 36386979

Group type: EXPERIMENTAL
Intervention: Somatic terminal case vignette
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Somatic non-terminal case vignette
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Mental non-terminal case vignette
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Ethical guidelines of the Swiss Medical Association (2004, 2018, 2022)
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Stigmatization of mentally ill people
Number of subjects: 20000
Study: 36386982

Group type: EXPERIMENTAL
Intervention: Risperidone treatment for 12 weeks
Number of subjects: 13
Study: 36387207

Group type: EXPERIMENTAL
Intervention: Fiducial markers implantation
Number of subjects: 15
Study: 36387835

Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 164

Group type: COMPARATOR
Intervention: Baseline characteristics
Number of subjects: 164
Study: 36387967

Group type: EXPERIMENTAL
Intervention: VYC-15L
Number of subjects: 163

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 163
Study: 36387989

Group type: EXPERIMENTAL
Intervention: CATCH Healthy Smiles intervention (classroom curriculum, toothbrushing routine, family outreach, and schoolwide coordinated activities) implemented for three years.
Number of subjects: 1020

Group type: COMPARATOR
Intervention: Control group offered free trainings and materials to implement a sun safety curriculum.
Number of subjects: 1020
Study: 36387991

Group type: EXPERIMENTAL
Intervention: Penetrating needle acupuncture
Number of subjects: 80

Group type: COMPARATOR
Intervention: Skin-touch placebo needle
Number of subjects: 80
Study: 36388001

Group type: EXPERIMENTAL
Intervention: Personalised Exercise Programme (PEP)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Approach (CBA)
Number of subjects: 367

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 367
Study: 36388199

Group type: EXPERIMENTAL
Intervention: Interdisciplinary team work using ICF model as a guide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multidisciplinary teamwork implementing neuroproprioceptive 'facilitation and inhibition' physiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multidisciplinary teamwork implementing technology-based physiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard multidisciplinary teamwork
Number of subjects: 0
Study: 36388237

Group type: EXPERIMENTAL
Intervention: Levodopa-Carbidopa Intestinal Gel (LCIG)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Optimized Medical Treatment (OMT)
Number of subjects: 87
Study: 36389188

Group type: EXPERIMENTAL
Intervention: OviTex® 1S
Number of subjects: 92
Study: 36389246

Group type: EXPERIMENTAL
Intervention: Vibrotactile feedback insole
Number of subjects: 4

Group type: COMPARATOR
Intervention: No feedback insole
Number of subjects: 4
Study: 36389355

Group type: EXPERIMENTAL
Intervention: Probiotic treatment (5 daily drops for 4 weeks)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 49
Study: 36389766

Group type: EXPERIMENTAL
Intervention: Anakinra (IL-1 receptor antagonist)
Number of subjects: 0
Study: 36394153

Group type: EXPERIMENTAL
Intervention: PF-06939999 at 0.5 mg, 4 mg, 6 mg, or 8 mg once daily (q.d.) or 0.5 mg, 1 mg, 2 mg, 4 mg, or 6 mg twice daily (b.i.d.)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: PF-06939999
Number of subjects: 28
Study: 36394250

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Behavioral Therapy (MBCBT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Treatment-as-usual (Control)
Number of subjects: 44
Study: 36394495

Group type: EXPERIMENTAL
Intervention: Nurse-led multi-component behavioural activation (N-MBA) programme
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study: 36394530

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes continual reassessment method (PRO-CRMB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5 + 2 stepwise design
Number of subjects: 0
Study: 36394692

Group type: EXPERIMENTAL
Intervention: Device-based analysis using prismaLine, Loewenstein Medical Technology
Number of subjects: 50

Group type: COMPARATOR
Intervention: Monitored polysomnography (PSG)
Number of subjects: 50
Study: 36394867

Group type: EXPERIMENTAL
Intervention: Avelumab 800 mg every 2 weeks and Talazoparib 1 mg once daily
Number of subjects: 200
Study: 36394892

Group type: EXPERIMENTAL
Intervention: Fluorescence lifetime imaging ophthalmoscopy (short spectral channel)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Fluorescence lifetime imaging ophthalmoscopy (long spectral channel)
Number of subjects: 19
Study: 36395084

Group type: EXPERIMENTAL
Intervention: Blue Light-Emitting Diode Therapy
Number of subjects: 0
Study: 36395401

Group type: EXPERIMENTAL
Intervention: Ziv-aflibercept 4 mg/kg intravenously on day 1 and 15 of a 28-day cycle (reduced to 2 mg/kg due to hypertension-related events)
Number of subjects: 19
Study: 36395492

Group type: EXPERIMENTAL
Intervention: SCS Microinjector® with triamcinolone acetonide injectable suspension (Xipere®)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SCS Microinjector®
Number of subjects: 0
Study: 36395818

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 215
Study: 36395989

Group type: EXPERIMENTAL
Intervention: Vortioxetine 10-20 mg/day for 8 weeks
Number of subjects: 0
Study: 36396038

Group type: EXPERIMENTAL
Intervention: International Classification of Diseases codes
Number of subjects: 51059

Group type: EXPERIMENTAL
Intervention: Birth certificate diagnosis
Number of subjects: 51059
Study: 36396301

Group type: EXPERIMENTAL
Intervention: Novel care pathway
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 0
Study: 36396307

Group type: EXPERIMENTAL
Intervention: IMU-838 + oseltamivir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oseltamivir
Number of subjects: 0
Study: 36396416

Group type: EXPERIMENTAL
Intervention: Delayed medical care (more than once)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delayed behavioral health care (more than once)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants who delayed care multiple times
Number of subjects: 0

Group type: COMPARATOR
Intervention: Participants who delayed care once or did not delay
Number of subjects: 0
Study: 36396498

Group type: EXPERIMENTAL
Intervention: Oteseconazole (VIVOJA)
Number of subjects: 0
Study: 36396665

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy with pyrotinib, letrozole, and dalpiciclib (5 cycles of 4-week treatment)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy with pyrotinib, letrozole, and dalpiciclib
Number of subjects: 79
Study: 36396738

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 36396947

Group type: EXPERIMENTAL
Intervention: Controlled feeding by uninfected Aedes aegypti mosquitos
Number of subjects: 30
Study: 36397054

Group type: EXPERIMENTAL
Intervention: Baseline MRI evaluation using the semi-quantitative MRI OA Knee Scoring (MOAKS) system
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Change in MRI features over 24 months
Number of subjects: 289
Study: 36398319

Group type: EXPERIMENTAL
Intervention: MicroRNA-15b/-106a/-374a impairment via transduction of human CD14 + monocytes
Number of subjects: 677

Group type: COMPARATOR
Intervention: No AMR samples
Number of subjects: 677
Study: 36398439

Group type: EXPERIMENTAL
Intervention: Entinostat (5 mg/week) plus exemestane (25 mg/day)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo plus exemestane (25 mg/day)
Number of subjects: 133
Study: 36398795

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (cohort 4)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus lenalidomide (cohort 5)
Number of subjects: 108
Study: 36398879

Group type: EXPERIMENTAL
Intervention: Self-directed, home-based walking intervention (150 min/week) using an activity tracker (FitbitTM)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Self-directed, home-based walking intervention
Number of subjects: 60
Study: 36398903

Group type: EXPERIMENTAL
Intervention: Lower blood pressure targets (135/85 mmHg or less)
Number of subjects: 9595

Group type: COMPARATOR
Intervention: Standard blood pressure targets (140 mmHg to 160mmHg/90 mmHg to 100 mmHg or less)
Number of subjects: 9595
Study: 36399037

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus tivozanib
Number of subjects: 0
Study: 36399068

Group type: EXPERIMENTAL
Intervention: JDQ443, a structurally novel, pyrazole-based, covalent inhibitor of KRAS
Number of subjects: 0
Study: 36399070

Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 0
Study: 36399131

Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Plasma neurofilament light chain (NfL) concentration
Number of subjects: 19
Study: 36399169

Group type: EXPERIMENTAL
Intervention: Home-Based Stress Management Toolkit (including animatronic social pets, weighted blankets, aromatherapy, etc.)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Home-Based Stress Management Toolkit
Number of subjects: 10
Study: 36399172

Group type: EXPERIMENTAL
Intervention: LGMDR9 participants
Number of subjects: 8
Study: 36399178

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) - regular cohort (3 initial monthly injections followed by injections every 2 months)
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) - irregular cohort with initial monthly injections
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) - irregular cohort without initial monthly injections
Number of subjects: 516
Study: 36399214

Group type: EXPERIMENTAL
Intervention: Noninvasive intracranial pressure waveforms (NICPW)
Number of subjects: 72
Study: 36399237

Group type: EXPERIMENTAL
Intervention: SCS-TA 4.0 mg (0.1 ml of 40 mg/ml)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control (sham)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: SCS-TA 4.0 mg
Number of subjects: 155
Study: 36399441

Group type: EXPERIMENTAL
Intervention: Simplified gating strategy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Original gating strategy
Number of subjects: 62
Study: 36399457

Group type: EXPERIMENTAL
Intervention: Gut microbiome assessment and cognitive function tests
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Colonic tissue biopsies and brain imaging
Number of subjects: 360
Study: 36399518

Group type: EXPERIMENTAL
Intervention: Minimal residual disease (MRD) detected in apheresis stem cell (ASC) samples
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Positive plasma MRD result post-ASCT
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Positive ASC MRD
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Post-ASCT surveillance MRD testing of plasma
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Overall study results
Number of subjects: 159
Study: 36399695

Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36399701

Group type: EXPERIMENTAL
Intervention: Interleukin-22 (F-652) combined with systemic corticosteroids
Number of subjects: 27
Study: 36399997

Group type: EXPERIMENTAL
Intervention: Baduanjin intervention group (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Health education control group (n = 30)
Number of subjects: 60
Study: 36400018

Group type: EXPERIMENTAL
Intervention: Whole-genome (WG) methylation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single nucleotide variants with paired white blood cell background removal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined scores from classifiers evaluated in this study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: cTAF (circulating tumor allele fraction)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical limit of detection (LOD) approaches
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WG methylation feature
Number of subjects: 0
Study: 36400069

Group type: EXPERIMENTAL
Intervention: Zanubrutinib 160 mg twice daily or 320 mg once daily
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Number of subjects: 67
Study: 36400106

Group type: EXPERIMENTAL
Intervention: Zanidatamab 20 mg/kg every 2 weeks (Part 2)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Zanidatamab (Part 1)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Zanidatamab (Part 2)
Number of subjects: 132
Study: 36400177

Group type: EXPERIMENTAL
Intervention: Cumulative tobacco smoke exposure (TSE)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Gestational vitamin D
Number of subjects: 476
Study: 36400184

Group type: EXPERIMENTAL
Intervention: hs-cTnT HEART Pathway (derivation cohort)
Number of subjects: 1452

Group type: EXPERIMENTAL
Intervention: hs-cTnT HEART Pathway (validation cohort)
Number of subjects: 1452
Study: 36400410

Group type: COMPARATOR
Intervention: HbA1c < 5.7% (Q1)
Number of subjects: 3994

Group type: EXPERIMENTAL
Intervention: 5.7% ≤ HbA1c < 6.1% (Q2)
Number of subjects: 3994

Group type: EXPERIMENTAL
Intervention: 6.1% ≤ HbA1c < 6.9% (Q3)
Number of subjects: 3994

Group type: EXPERIMENTAL
Intervention: HbA1c ≥ 6.9% (Q4)
Number of subjects: 3994
Study: 36400531

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study: 36401081

Group type: EXPERIMENTAL
Intervention: OC-01 (varenicline solution) nasal spray 0.03 mg
Number of subjects: 449

Group type: COMPARATOR
Intervention: Vehicle control (VC)
Number of subjects: 449
Study: 36401179

Group type: EXPERIMENTAL
Intervention: Cervarix HPV vaccination
Number of subjects: 12118

Group type: COMPARATOR
Intervention: No HPV vaccination
Number of subjects: 12118
Study: 36401237

Group type: EXPERIMENTAL
Intervention: Glycemic variability measured using continuous glucose monitoring system (CGMS) over a 10-day period
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Self-reported questionnaires assessing eating behaviors, diabetes self-management skills, anxiety disorders, depression disorder, diabetes literacy and numeracy skills, cognitive flexibility, attention deficit, level of interoception, and impulsivity behaviors
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Qualitative phase with individual in-depth face-to-face (virtual) interviews
Number of subjects: 150